Objective: Intravenous methylprednisolone (IVMP) is recommended as the first-line treatment for moderate-to-severe and active thyroid-associated ophthalmopathy (TAO). This study aimed to identify potential predictors and establish a multivariable prediction model for the efficacy of IVMP therapy.
| INTRODUC TI ON
Thyroid-associated ophthalmopathy (TAO) is a complex autoimmune inflammatory disorder that is the most prevalent extrathyroidal manifestation of Graves' disease. lates the secretion of pro-inflammatory cytokines and chemokines, the production of hyaluronic acid and adipogenesis, resulting in connective tissue remodelling, extraocular muscle enlargement and orbital fat expansion. 2, 3 In addition to TSHR activation, recent studies suggest a synergistic role of the insulin-like growth factor-1 (IGF-1)
receptor in TSHR-initiated signalling. 2, 3 Thyroid-associated ophthalmopathy has an annual adjusted incidence of 16 women and three men per 100 000 people. 4 Common clinical manifestations include eyelid retraction, proptosis, diplopia and even vision loss caused by compressive optic neuropathy.
It has a typical self-limiting course characterized by an initial active phase of inflammation and rapid progression, reaching its peak after 6-24 months, followed by a chronic, stable phase during which regression of inflammation and mechanical restrictions due to pronounced fibrosis is often observed. 5 Current available interventions for moderate-to-severe and active TAO consist of glucocorticoids (GCs), radiotherapy and some immune modulators, such as rituximab and teprotumumab. 6 As recommended by the recent consensus statement of the European Group on Graves' Orbitopathy (EUGOGO), intravenous methylprednisolone (IVMP) remains the first-line treatment for moderate-to-severe and active TAO. However, the response rate for IVMP therapy varies from 52% to 80% according to several previous randomized clinical trials testing different GC dosages and administration protocols. [8] [9] [10] Thus far, the prognostic factors associated with therapeutic efficacy are inadequately understood. Therefore, it is critical to identify the potential predictors of therapeutic efficacy to help determine the indication and prognosis of IVMP therapy. Moreover, identification of modifiable predictors could provide practical intervention targets in the management of TAO patients to improve therapeutic efficacy.
Hence, the present retrospective study aimed to identify potential predictors and establish a multivariable prediction model for the efficacy of IVMP therapy in a large cohort of patients with moderate-to-severe and active TAO.
| ME THODS

| Study design and patients
This study retrospectively collected data of all consecutive pa- having not completed the full course of IVMP therapy; and (c) incomplete data on ophthalmic assessments and/or important laboratory measurements.
The treatment protocol was as follows: a dose of 0.5-1.0 g intravenous methylprednisolone every other day for three times in a course, repeated at intervals of 20 days, for a total of three courses (4.5-9.0 g cumulative dose). During the course of treatment, all patients were prescribed proton pump inhibitors or H2 receptor antagonists and calcium supplements. A low-salt diet, sleeping on an elevated pillow and sunglasses were recommended, and antithyroid agents or thyroxine were used to restore and maintain euthyroidism.
Smokers were advised to refrain from smoking.
The eligible participants were divided into two sequential sets by were defined as those who had already quit smoking before the treatment or stopped smoking from the beginning of the treatment, whereas those who still smoked during the therapy were classified as current smokers. Elevated TSH levels were defined as >5 μIU/mL at any measurement during the treatment.
| Data collection and outcome evaluation
Results of ophthalmic assessments before and after IVMP therapy were compared to evaluate therapeutic outcomes, which were divided into "responsive" and "unresponsive." "Responsive" was defined as the achievement of at least three of the following improve- 
| Statistical analysis
Continuous variables with a normal distribution are presented as means ± SDs; otherwise, they are expressed as medians and 25th- Chicago, IL, USA). P < 0.05 was considered statistically significant.
| RE SULTS
| Characteristics of the patients in the training and validation sets
From January 2010 to May 2018, 502 consecutive TAO patients were admitted to the Department of Endocrinology, First were in the training set and 12 (11.8%) were in the validation set, and there was no significant difference between these two ratios (P = 0.512).
The characteristics of the patients are listed in validation sets. In particular, there was no significant difference in the response rates between the two sets (53% vs 55.9%, P = 0.635).
However, the cumulative dose of IVMP was significantly higher in the training set than in the validation set (9.0 [5.5, 9.0] g vs 4.5 [4.5,
5
.5] g, P < 0.001).
| Results of univariate logistic regression analysis in the training set
Factors associated with the efficacy of IVMP therapy were first assessed by univariate analysis. As shown in Table 2 , pretreatment CAS (P < 0.001), positive pretreatment TRAB levels (P < 0.001), high pretreatment triglyceride levels (P < 0.001), duration of eye symptoms (P = 0.001), history of radioiodine therapy (P = 0.011) and elevated TSH levels during treatment (P = 0.016) were associated with the efficacy of IVMP therapy.
In addition, we analysed the relationship between the efficacy of IVMP therapy and the absolute levels of pretreatment TRAB and triglycerides. As a result, the median levels of pretreatment TRAB were significantly higher in unresponsive patients than in responsive pa- The results on triglycerides are introduced in detail below.
| Relationship between the pretreatment triglyceride levels and the efficacy of IVMP therapy in the training set
The proportion of patients with high pretreatment triglyceride levels (≥150 mg/dL as defined by the European Society of (Figure 2A ). Interestingly, this value was very close to 150 mg/dL, the cut-off value for high triglyceride levels established by the ESC. Table 3 , these factors did not differ between these two groups.
| Potential predictors and the multivariable prediction model for the efficacy of IVMP therapy in the training set
Subsequent multivariate logistic regression analysis showed that pretreatment CAS (OR = 3.506, P < 0.001), positive pretreatment TRAB levels (OR = 0.061, P < 0.001), high pretreatment triglyceride levels (OR = 0.090, P = 0.001), duration of eye symptoms (OR = 0.878, P = 0.017) and elevated TSH levels during treatment (OR = 0.145, P = 0.005) were independently associated with therapeutic efficacy (Table 4) .
According to the ROC curve analysis, the optimal cut-off value of the duration of eye symptoms was 15 months with an AUC of 0.633 (95% CI, 0.557-0.709, P = 0.003), sensitivity of 100% and specificity of 30.6% ( Figure 2B ). The optimal cut-off value of pretreatment CAS was 2.5 with an AUC of 0.792 (95% CI, 0.726-0.858, P < 0.001), sensitivity of 87.1% and specificity of 60.2% ( Figure 2C ).
Furthermore, a multivariable prediction model was established with all the independent factors based on the result of multivariate logistic regression analysis.
| Model performance in the training and validation sets
The multivariable prediction model showed excellent discrimination in the training set with an AUC of 0.915 (95% CI, 0.864-0.967, P < 0.001) ( Figure 2D ). In the validation set, similar performance (AUC = 0.885, 95% CI, 0.812-0.957, P < 0.001) was observed ( Figure 2E ). Hosmer-Lemeshow goodness of fit tests demonstrated good calibration of this model in both the training and validation sets (P = 0.518 and P = 0.752, respectively).
| D ISCUSS I ON
The present study identifies several potential predictors for the efficacy of IVMP therapy in patients with moderate-to-severe and active TAO. In addition to a low pretreatment CAS, positive pretreatment TRAB levels, prolonged duration of eye symptoms and elevated TSH levels during treatment, the present results indicate that high pretreatment triglyceride levels might also negatively affect therapeutic efficacy.
A higher pretreatment CAS suggests an increased disease activity that is more likely to be attenuated by IVMP therapy. 13 As defined by the EUGOGO, a CAS ≥3/7 is sufficient for the diagnosis of active TAO. 7 Nevertheless, this criterion was established in Caucasian patients, and previous studies have reported considerably lower rates of eyelid redness present in Asian patients than in Caucasian patients (5.13%-10.26% vs 53.5%), 10,13 which might be attributed to the differences in eyelid anatomy between Caucasian and Asian populations. 14 This discrepancy makes it possible that the cut-off point for CAS in Asian patients might be <3/7.
Therefore, in the present study, patients with a CAS <3/7 but with extraocular muscle enlargements shown by orbital CT scanning or MRI were also included. These patients showed significantly lower response rate than patients with a CAS ≥3/7 (10.3% vs 50.3%, P < 0.001), which is consistent with the present finding that IVMP therapy is more effective when the CAS is >2.5 according to the optimal cut-off value (sensitivity of 87.1% and specificity of 60.2%). The present finding is consistent with the results from a previous study also conducted in Asian patients. 15 However, large prospective studies in different populations are required to substantiate this finding.
It is generally accepted that TRAB plays an indispensable role in the pathogenesis of TAO. The proportion of patients treated with intravenous or oral glucocorticoids more than 3 months before IVMP therapy was analysed since patients who received these therapies within the previous three months were excluded from this study.
inhibitory autoantibodies, correlate with the activity and severity of TAO, 16, 17 the relationship between these autoantibodies and the ef- According to the present optimal cut-off value, IVMP treatment is more effective in patients with a disease duration within 15 months. Thus, early diagnosis and prompt treatment are highly recommended for patients with moderate-to-severe and active TAO. Of note, although extremely sensitive (100%), the duration of eye symptoms is not very specific (30.6%) in predicting the therapeutic response. A possible explanation is that immunosuppressive therapies exert their beneficial effects only in the active phase of the disease, 18 but the duration of the active phase might vary considerably, so the total duration of eye symptoms alone may not be an ideal predictive factor, which is supported by several previous studies. 13, 19 Therefore, it is recommended that the duration of eye symptoms should be used in combination with other prognostic factors to predict therapeutic efficacy.
Thyroid dysfunction has been associated with the risk, severity and therapeutic efficacy of TAO. 1, 15, 20 Therefore, the present study specifically assessed the impact of elevated TSH levels on therapeutic efficacy. Patients were dichotomized into those with TSH levels ≤5 μIU/mL at all measurements and those with levels >5 μIU/mL at any measurement during the treatment. There was a significantly worse response in patients with at least one TSH value >5 μIU/mL than in those with TSH levels ≤5 μIU/mL at all tests (OR = 0.145, Table 3 ).
The mechanisms responsible for the relationship between high triglyceride levels and poor therapeutic efficacy are unknown and require further investigation. It has been suggested that a range of autoimmune diseases is associated with hyperlipidemia. 25 Under conditions of hyperlipidemia, self-lipid antigens might be presented to lipid-specific autoreactive T cells, resulting in the activation of pathogenic T cells, the secretion of Th1, Th2 and Th17 cytokines and the subsequent development of autoimmune diseases. 25 In addition, the increased free fatty acid levels in the liver might cause dysfunction of the mitochondria and endoplasmic reticulum in hepatocytes, leading to the release of reactive oxygen species. 26 Given that both 34 Another recent retrospective study of 90 patients reported that smoking was not associated with the efficacy of IVMP therapy. 15 In the present study, we did not find a significant correlation between smoking and therapeutic efficacy either. A possible reason for this discrepancy might be the different methods for classifying smoking status. In the observational study, patients were divided into never-smokers, active smokers and passive smokers. 33 However, because of the retrospective design of this study, it was hard to judge whether each patient was a passive smoker or not, we classified patients as never smokers, ex-smokers and current smokers referencing several studies published in respected journals that divided participants into smokers (current smokers) and nonsmokers. 6, 29 The other two retrospective studies mentioned above did not take passive smoking into account either. 15, 34 Therefore, future studies with large sample sizes are still needed to investigate the impact of different smoking status on the efficacy of IVMP therapy in TAO patients.
Another issue of this study is the significant difference in the cumulative dose of IVMP between the training and validation sets.
The training and validation sets were defined by splitting the data set by time. All the patients in the training set received IVMP therapy before July 2015, and most of them were treated with a high-dose regimen (9.0 g cumulative dose). While patients in the validation set underwent IVMP therapy thereafter, and most of them were treated with an intermediate-dose schedule (4.5 g cumulative dose) according to the 2016 EUGOGO recommendations. 7 We divided the data set by time, because this method allows for non-random variation and represents a stronger design for evaluating predictive performance than random splitting of the sample. 35 Indeed, there was apparent difference in the cumulative dose of IVMP between the two sets (Table 1 ). Yet, as described in the results, the multivariable prediction model showed similarly good discrimination and calibration in the two sets.
In addition, a large number (around 40%) of potential patients were excluded from this study (Figure 1) , although the final sample size (302 patients) was still much larger than that of the similar investigations, 15, 33, 34 the present retrospective study may therefore be less generalizable.
In conclusion, the present study provides novel insights into the factors associated with the efficacy of IVMP therapy. A multivariable prediction model has been established and validated. Moreover, several practical suggestions have been made in the management of TAO patients to improve therapeutic efficacy. However, further prospective studies are required to verify these findings and assess the impact that modifying these factors might exert on therapeutic efficacy. Research and Development Project of Shaanxi Province (grant no.
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